Diverticulitis Drugs Market Size & Share, by Drug Type {Antibiotics (Metronidazole, Amoxicillin, Moxifloxacin), Dietary Fiber}; Route of Administration (Oral, Intravenous); Distribution Channel (Online, Offline); End-user (Specialty Clinics, Hospitals, Research Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2029

Global Diverticulitis Drugs Market Highlights over 2020-2029

The global diverticulitis drugs market is anticipated to record a significant CAGR over the forecast period, i.e., 2021-2029. This growth can be attributed to the growing prevalence of obesity, rising old age population, and the inclination of youth towards an unhealthy lifestyle. Moreover, eating excessive red meat, and lack of fiber in diet can also lead to diverticulitis. According to a report by the World Health Organization, more than 2 billion people in the world do not have access to a balanced diet. In another report of the WHO, it is stated that around 1.9 billion adults were overweight and 650 million were obese, in the year 2016. In fact, at present, there are more overweight individuals than underweight, globally. This is estimated to elevate the prevalence of diverticulitis, which in turn, is estimated to boost the market growth. Additionally, factors such as government initiatives and support to treat the disease, rising demand for advanced treatment options, and growing market players offering newer products, are anticipated to drive the growth of the market over the coming years. CLICK TO DOWNLOAD SAMPLE REPORT

The global diverticulitis drugs market is segmented by end-user into specialty clinics, hospitals, research centers, and others. Among these, the hospitals segment is anticipated to hold the largest market share over the forecast period on the back of symptoms and complications associated with the disease. Its symptoms include cramps on the left side of the abdomen which goes away after passing gas or stool, abdominal pain, fever, diarrhea, bloating, bleeding from rectum, bright red blood in stool, and others, which often need immediate attention from medical staff.

Major Macro-Economic Indicators Impacting the Market Growth

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Diverticulitis Drugs Market Regional Synopsis

On the basis of regional analysis, the global diverticulitis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa region.

The market in the North America is anticipated to hold the largest market share over the forecast period on account of rising obese population, and availability of advanced treatment options. Additionally, the growing cases of various gastrointestinal diseases, including diverticulitis, is estimated to boost the market growth. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in the United States, about 58% of the individuals above 60 years of age have diverticulosis and about 5% of people with diverticulosis tends to develop diverticulitis. According to another report by the NIDDK, around 200,000 individuals are hospitalized for diverticulitis each year in the United States.

The market in the Asia Pacific is anticipated to grow at the highest CAGR over the forecast period owing to the growing number of patients, rising awareness among the individuals regarding health, availability of new treatment methods, improvement in the standard of living, and rapidly improving health care infrastructure.

The global diverticulitis drugs market is further classified on the basis of region as follows:

• North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis.
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis.
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis.
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
• Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis.

Market Segmentation

Our in-depth analysis of the global diverticulitis drugs market includes the following segments:

By Drug Type

• Antibiotics
  • Metronidazole
  • Amoxicillin
  • Moxifloxacin
  • Others
• Dietary Fiber
• Others

By Route of Administration

• Oral
• Injection

By Distribution Channel

• Online
• Offline

By End-User

• Specialty Clinics
• Hospitals
• Research Centers
• Others

Growth Drivers

• Increasing Trend of Sedentary Lifestyle and Unhealthy Diet
• Increasing Global Geriatric Population

Restraints

• Lack of Awareness among People Regarding the Disease
• Stringent Regulations of the Government Regarding the Approval of Medicines

Top Featured Companies Dominating the Market

• Emmaus Life Sciences, Inc.
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis
• Synergy Pharma
• Abbott Laboratories
• GlaxoSmithKline plc
•  Ardelyx, Inc.
• Gilead Sciences, Inc.
• Trumac Healthcare
• Pfizer Inc.
• Hikma Pharmaceuticals PLC
• Takeda Pharmaceutical Company Limited